Across TCGA pan-cancer cohorts, IGLV3-25 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGLV3-25 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IGLV3-25 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV3-25 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where IGLV3-25 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.198	0.595	.001	36	view →
UCEC	OS	Tertile	All	0.873	1.000	.011	18	view →
HNSC	DFS	Quartile	IV	0.858	0.538	.006	15	view →
CCRCC	DFS	Tertile	II,III,IV	0.198	0.887	.024	12	view →
LUAD	OS	Quartile	All	0.506	0.840	.021	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGLV3-25 tumor-vs-normal RNA expression · all IGLV3-25 data types